An LC-MS/MS Method Development and Validation for the Quantification of Infigratinib in K2EDTA Human Plasma
Abstract
A validated liquid chromatography with tandem mass spectrometry (LC-MS-MS) technology was developed for the quantification of infigratinib, using a simple and specific approach. This method utilizes a liquid-liquid extraction (LLE) strategy to achieve high sensitivity. The analytical approach that was developed underwent validation in terms of many characteristics including specificity, sensitivity, carry-over, recovery, precision, matrix effect, accuracy, and stability. The elution of the drug and IS occurred in a time frame of 6.5 minutes using a PhenomenexSB-C18 column (250 × 4.6 mm x 5 μm). The mobile phase consisted of a mixture of acetonitrile and 0.1% v/v formic acid in water, with a ratio of 80:20. The infusion flow rate was set at 0.9 mL/min. The retention times (RT) of infigratinib and IS were determined to be 5.12 and 3.31 minutes, respectively. The elution time required for complete separation of infigratinib was 6.5 minutes. The equation of the linear regression line was determined to be y = 0.994x + 2.662, and the coefficient of determination (r2) was calculated to be 0.999. The coefficient of variation (%CV) obtained for the calibration graph of infigratinib was determined to be less than or equal to 3.73. The matrix effect was assessed by calculating the coefficient of variation (%CV) for the High and low quality control (QC) samples, yielding values of 1.64 and 0.70% respectively.
Keywords:
Infigratinib, Giant-cell tumor, LC-MS/MS, Healthy rabbits, Bioavailability studiesDOI
https://doi.org/10.25004/IJPSDR.2024.160112References
Botrus G, Raman P, Oliver T, Bekaii-Saab T. Infigratinib (BGJ398): an investigational agent for the treatment of FGFR-altered intrahepatic cholangiocarcinoma. Expert OpinInvestig Drugs. 2021;30(4):309- 316. Available formdoi: 10.1080/13543784.2021.1864320.
Blechacz B. Cholangiocarcinoma: Current Knowledge and New Developments. Gut Liver. 2017;11(1):13-26. Available formdoi: 10.5009/gnl15568.
Lima NC, Atkinson E, Bunney TD, Katan M, Huang PH. Targeting the Src Pathway Enhances the Efficacy of Selective FGFR Inhibitors in Urothelial Cancers with FGFR3 Alterations. Int J Mol Sci. 2020;21(9):21093214. Available formdoi: 10.3390/ijms21093214.
FDA Approved Drug Products: TRUSELTIQ (infigratinib) capsules, for oral use.https://www.accessdata.fda.gov/drugsatfda_docs/ label/2021/214622s000lbl.pdf
Mostafa GAE, Kadi AA, AlMasoud N, Attwa MW, Al-Shakliah NS, AlRabiah H. LC-MS/MS method for the quantification of the anti-cancer agent infigratinib: Application for estimation of metabolic stability in human liver microsomes. J Chromatogr B AnalytTechnol Biomed Life Sci. 2021;1179:122806. Available form DOI: 10.1016/j. jchromb.2021.122806
Nirav P Patel, Mallika Sanyal, Naveen Sharma, Dinesh S Patel, Pranav S Shrivastav, Bhavin N Patel. Highly sensitive LC–MS/MS method to estimate doxepin and its metabolite nordoxepin in human plasma for a bioequivalence study Highly sensitive LC–MS/MS method to estimate doxepin and its metabolite nordoxepin in human plasma for a bioequivalence study. J Pharm Anal. 2017; 6:145-50. Available form https://doi.org/10.1016/j.jpha.2017.06.004
Yen-An Chen, Kuang-Yang Hsu. Development of a LC-MS/MS-based method for determining metolazone concentrations in human plasma: Application to a pharmacokinetic study. J food drug anal. 2013; 21:154-9.Available form https://doi.org/10.1016/j. jfda.2013.05.004
Jaiv ik V, Sha haPr iyank a A , Sha haPr iya V, Sha hbMa llik a, SanyalcPranav S, Shrivastav. Fast and sensitive LC–MS/MS method for the simultaneous determination of lisinopril and hydrochlorothiazide in human plasma.J Pharm Anal. 2017;7:163– 169. Available formdoi: 10.1016/j.jpha.2016.11.004
ICH guidelines for validation of analytical procedures: text and methodology. Q2(R1) ICH, Geneva; 2005. p. 1-14.Available form
US FDA, Guidance for Industry Bioanalytical Method Validation, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Rockville, Maryland, USA, 2001.
Rana S, Uralets VP, Ross W. A new method for simultaneous determination of cyclic antidepressants and their metabolites in urine using enzymatic hydrolysis and fast GC-MS, J Anal Toxicol. 2008;32:355–363.Available form DOI: 10.1093/jat/32.5.355
Titier K, Castaing N, Le-Deodic M. Quantification of tricyclic antidepressants and monoamine oxidase inhibitors by high-performance liquid chromatography-tandem mass spectrometry in whole blood. J Anal Toxicol. 1997;21:200–207.Available form DOI: 10.1093/jat/31.4.200
Patel DS, Sharma N, Patel MC. Development and validation of a selective and sensitive LC–MS/MS method for determination of cycloserine in human plasma: application to bioequivalence study. J. Chromatogr B. 2011;879: 2265–2273.Available formdoi: 10.1016/j. jchromb.2011.06.011.
Shashidhar Reddy D, PrakashRao and Devaraj VC. A Highly Sensitive LC-Ms/Ms Method for Determination of Desvenlafaxine in Rabbit Plasma and its Application to Rabbit Pharmacokinetic Study. J Anal Bio Tech. 2011; 2(5): 2-6. Available formDOI:10.4172/2155- 9872.1000125
Published
Abstract Display: 377 
PDF Downloads: 291 
